Listing of Targovax ASA at Oslo Børs

Targovax is a clinical stage immuno-oncology company dedicated to the development of immunotherapies for cancer patients. Targovax is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and an oncolytic virus platform based on engineered viruses armed with potent immune-stimulating transgenes for patients with solid tumors.

Quotes, details on the share and the company, notifications and historical prices